CN121086085A - 新型白介素-15 (il-15)融合蛋白及其用途 - Google Patents

新型白介素-15 (il-15)融合蛋白及其用途

Info

Publication number
CN121086085A
CN121086085A CN202511239681.1A CN202511239681A CN121086085A CN 121086085 A CN121086085 A CN 121086085A CN 202511239681 A CN202511239681 A CN 202511239681A CN 121086085 A CN121086085 A CN 121086085A
Authority
CN
China
Prior art keywords
domain
fusion protein
seq
amino acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511239681.1A
Other languages
English (en)
Chinese (zh)
Inventor
李跃升
芮凌云
徐静
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keyou Gene Co
Original Assignee
Keyou Gene Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keyou Gene Co filed Critical Keyou Gene Co
Publication of CN121086085A publication Critical patent/CN121086085A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202511239681.1A 2018-06-22 2019-06-20 新型白介素-15 (il-15)融合蛋白及其用途 Pending CN121086085A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862689051P 2018-06-22 2018-06-22
US62/689,051 2018-06-22
CN201980055119.XA CN112584851B (zh) 2018-06-22 2019-06-20 新型白介素-15(il-15)融合蛋白及其用途
PCT/US2019/038210 WO2019246379A1 (en) 2018-06-22 2019-06-20 Novel interleukin-15 (1l-15) fusion proteins and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980055119.XA Division CN112584851B (zh) 2018-06-22 2019-06-20 新型白介素-15(il-15)融合蛋白及其用途

Publications (1)

Publication Number Publication Date
CN121086085A true CN121086085A (zh) 2025-12-09

Family

ID=68984274

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202511239681.1A Pending CN121086085A (zh) 2018-06-22 2019-06-20 新型白介素-15 (il-15)融合蛋白及其用途
CN201980055119.XA Active CN112584851B (zh) 2018-06-22 2019-06-20 新型白介素-15(il-15)融合蛋白及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980055119.XA Active CN112584851B (zh) 2018-06-22 2019-06-20 新型白介素-15(il-15)融合蛋白及其用途

Country Status (8)

Country Link
US (2) US12319722B2 (cg-RX-API-DMAC7.html)
EP (1) EP3810171B1 (cg-RX-API-DMAC7.html)
JP (2) JP7440102B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250130696A (cg-RX-API-DMAC7.html)
CN (2) CN121086085A (cg-RX-API-DMAC7.html)
AU (2) AU2019288471B2 (cg-RX-API-DMAC7.html)
CA (1) CA3102821A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019246379A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24546B1 (es) * 2016-12-30 2021-09-07 Ct Ingenieria Genetica Biotecnologia Composición vacunal que comprende un mutante de la interleucina-15 humana
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN109705211B (zh) 2017-10-26 2020-08-18 苏州复融生物技术有限公司 一种IgG1 Fc单体及其应用
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
KR20220114063A (ko) * 2019-12-13 2022-08-17 큐진 인크. 신규한 인터루킨-15 (il-15) 융합 단백질 및 이의 용도
AU2021260989A1 (en) * 2020-04-22 2022-11-17 Novartis Ag Pharmaceutical compositions and pharmaceutical products of heterodimeric human interleukin-15 (hetIL-15)
KR20250140647A (ko) * 2020-08-03 2025-09-25 난트셀, 인크. Il-15 초작용제에 대한 약물-특이적 약동학 검정
EP4206219A1 (en) * 2020-08-31 2023-07-05 GI Cell, Inc. Fusion protein including il15 protein, il15 receptor alpha protein, fc domain, and il2 protein, and use thereof
KR20230104866A (ko) * 2020-09-16 2023-07-11 베이진 엘티디 인터류킨 15 작제물 및 사용 방법
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
CN113321736B (zh) * 2020-12-30 2024-01-09 苏州复融生物技术有限公司 一种长效化白介素15融合蛋白及其制备方法和应用
US20250197525A1 (en) * 2021-04-28 2025-06-19 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
CN116375888A (zh) * 2021-05-08 2023-07-04 上海交通大学 一种融合蛋白及其制备方法和用途
EP4346875A4 (en) * 2021-05-28 2025-04-16 Akso Biopharmaceutical, Inc. BISPECIFIC FC FUSION PROTEINS WITH SPD-1 AND IL-15
CN116655771A (zh) * 2021-05-28 2023-08-29 苏州复融生物技术有限公司 一种新型白介素15突变体多肽的开发及其应用
US20240350589A1 (en) 2021-08-13 2024-10-24 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
CN116023503B (zh) * 2021-10-25 2024-05-31 上海交通大学 一种融合蛋白及其制备方法和用途
EP4435011A4 (en) * 2021-11-15 2025-07-16 Inst Biophysics Cas FUSION PROTEIN CONSTRUCTION TAKING INTERLEUKIN 15 AS ACTIVE INGREDIENT AND USE THEREOF
CN115141283A (zh) * 2022-03-10 2022-10-04 厦门柏慈生物科技有限公司 一种融合蛋白、制备方法及其应用
WO2024039973A2 (en) * 2022-08-05 2024-02-22 Staidson Biopharma Inc. Masking polypeptide, activatable novel prodrugs and methods of use thereof
WO2024091794A1 (en) * 2022-10-28 2024-05-02 Nant Holdings IP, LLP Vaccine composition for stimulation of broad-spectrum memory of b cell expansion
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
KR20050049545A (ko) * 2002-10-14 2005-05-25 에프. 호프만-라 로슈 아게 길항제 il-15
ES2367027T3 (es) 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
EP2173378B1 (en) 2007-06-27 2014-03-19 Admune Therapeutics LLC Complexes of il-15 and il-15ralpha and uses thereof
JP6251570B2 (ja) * 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体il−15可溶性融合分子並びにその製造及び使用方法
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
US20150359853A1 (en) * 2012-10-24 2015-12-17 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
EP3093295B1 (en) 2014-01-08 2020-05-27 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-15 heterogeneous dimer protein and uses thereof
US10335460B2 (en) 2014-07-29 2019-07-02 Novartis Ag IL-15 and IL-15Rα heterodimer dose escalation regimens for treating conditions
US10905743B2 (en) 2014-12-19 2021-02-02 Jiangsu Hengrui Medicine Co., Ltd. Interleukin 15 protein complex
CN112574316A (zh) 2015-07-02 2021-03-30 博际生物医药科技(杭州)有限公司 用于肿瘤靶向治疗的白细胞介素-15融合蛋白
US10858452B2 (en) * 2015-09-16 2020-12-08 Insitut National de la Sante et de la Recherche Medicale (INSERM) Specific interleukin-15 (IL-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
MX2019004327A (es) 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains

Also Published As

Publication number Publication date
WO2019246379A1 (en) 2019-12-26
US12319722B2 (en) 2025-06-03
AU2025201175A1 (en) 2025-03-13
CN112584851A (zh) 2021-03-30
US20220106374A1 (en) 2022-04-07
US20250388641A1 (en) 2025-12-25
KR20210033994A (ko) 2021-03-29
EP3810171A4 (en) 2022-04-06
CA3102821A1 (en) 2019-12-26
EP3810171A1 (en) 2021-04-28
KR20250130696A (ko) 2025-09-02
CN112584851B (zh) 2025-09-05
EP3810171C0 (en) 2025-07-09
KR102848197B1 (ko) 2025-08-21
AU2019288471A1 (en) 2021-01-14
JP2021528104A (ja) 2021-10-21
JP2024063004A (ja) 2024-05-10
JP7440102B2 (ja) 2024-02-28
JP7741574B2 (ja) 2025-09-18
EP3810171B1 (en) 2025-07-09
AU2019288471B2 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
CN112584851B (zh) 新型白介素-15(il-15)融合蛋白及其用途
CN115087464B (zh) 新型白介素-15(il-15)融合蛋白及其用途
CN114651004B (zh) 用于癌症治疗的新型白介素-2变体
JP2022536347A (ja) 新規インターロイキン-2バリアントおよびその二官能性融合分子
CN120349426A (zh) 白介素-2变体及其使用方法
JP6484634B2 (ja) Il−15ヘテロ二量体タンパク質及びその用途
RU2833537C2 (ru) Новые варианты интерлейкина-2 для лечения рака
HK40074638A (en) Novel interleukin-2 variants for the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination